(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.08%) $79.06
(0.31%) $1.938
(0.90%) $2 331.80
(0.76%) $26.95
(1.11%) $965.50
(0.00%) $0.933
(-0.04%) $11.03
(-0.07%) $0.798
(0.06%) $93.51
Quarter results today
(bmo 2024-05-01)
Expected move: +/- 4.95%
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
Dagens volum | 3.78M |
Gjennomsnittsvolum | 3.66M |
Markedsverdi | 8.54B |
EPS | £0 ( 2024-02-27 ) |
Last Dividend | £18.38 ( 2023-03-30 ) |
Next Dividend | £0 ( N/A ) |
P/E | 40.69 |
ATR14 | £0.953 (0.10%) |
Volum Korrelasjon
Smith & Nephew plc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Smith & Nephew plc Korrelasjon - Valuta/Råvare
Smith & Nephew plc Økonomi
Annual | 2023 |
Omsetning: | £5.55B |
Bruttogevinst: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2023 |
Omsetning: | £5.55B |
Bruttogevinst: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2022 |
Omsetning: | £5.22B |
Bruttogevinst: | £3.68B (70.47 %) |
EPS: | £0.250 |
FY | 2021 |
Omsetning: | £5.21B |
Bruttogevinst: | £3.67B (70.40 %) |
EPS: | £0.598 |
Financial Reports:
No articles found.
Smith & Nephew plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£12.91 (N/A) |
£0 (N/A) |
£18.38 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £3.45 | 1993-05-10 |
Last Dividend | £18.38 | 2023-03-30 |
Next Dividend | £0 | N/A |
Payout Date | 2023-05-17 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | £440.59 | -- |
Avg. Dividend % Per Year | 1.26% | -- |
Score | 4.16 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.99 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £26.91 | 1.93% |
2019 | £28.49 | 1.99% |
2020 | £29.73 | 1.62% |
2021 | £27.12 | 1.73% |
2022 | £31.31 | 2.40% |
2023 | £18.38 | 1.64% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
STEM.L | Dividend Knight | 2023-11-09 | Annually | 19 | 1.82% | |
JTC.L | Dividend Knight | 2023-09-21 | Semi-Annually | 7 | 0.79% | |
CBOX.L | Dividend Knight | 2023-07-27 | Semi-Annually | 7 | 2.27% | |
PSON.L | Dividend King | 2023-08-10 | Semi-Annually | 32 | 1.90% | |
GEC.L | Dividend Knight | 2023-09-25 | Quarterly | 22 | 0.24% | |
AJIT.L | Dividend Junior | 2023-09-14 | Semi-Annually | 16 | 1.25% | |
TND.L | Dividend Junior | 2023-05-11 | Semi-Annually | 31 | 1.44% | |
LUCE.L | Dividend Knight | 2023-09-14 | Annually | 8 | 2.16% | |
COST.L | Dividend Knight | 2023-09-21 | Annually | 17 | 0.27% | |
RST.L | Dividend Junior | 2023-09-21 | Annually | 13 | 0.98% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0474 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0503 | 1.500 | -0.552 | -0.828 | [0.1 - 1] |
payoutRatioTTM | 1.243 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.569 | 0.800 | -1.359 | -1.087 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.85 | -7.28 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.591 | -1.500 | 7.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.701 | 1.000 | 1.644 | 1.644 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.123 | 1.000 | 9.54 | 9.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.197 | 1.000 | -0.0159 | -0.0159 | [0.2 - 2] |
assetTurnoverTTM | 0.556 | 0.800 | 9.63 | 7.70 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.63 | 1.000 | 6.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0503 | 2.50 | -0.355 | -0.828 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.93 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.87 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.243 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.110 | 1.000 | 9.76 | 0 | [0.1 - 0.5] |
Total Score | 4.99 |
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.